Soft mist inhaler for PAH result of joint venture between Thaerapy and Resyca

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags soft mist inhaler Thaerapy BV Resyca BV pulmonary arterial hypertension Blood vessel

A soft mist inhaler made by Resyca BV, a joint venture of Medspray Pharma BV and Recipharm AB, is being brought to patients with pulmonary arterial hypertension (PAH).

Thaerapy BV, a pharmaceutical drug product development company announced its joint venture with Resyca after the signing of an exclusive license agreement for the inhaler for the development of a treatment of PAH.

As part of the agreement, Resyca will receive a signing milestone as well as other milestones for the supply of soft-mist inhalers for Thaerapy’s clinical trials. Additionally, Resyca will receive a royalty based on net sales of the drug-device combination once it is marketed. Resyca and Thaerapy have also agreed on a joint work plan for the comprehensive development program.

As part of the contracted services, Resyca will provide Thaerapy with its proprietary soft mist inhalers, which are based on pre-filled syringes. Resyca will also offer services for compounding, filling and finishing of the drug product in the inhaler. Furthermore, Resyca will also support Thaerapy in the creation of the necessary regulatory and clinical trial submission documents.

Soft mist inhaler technology 

“We are thrilled to be partnering with Thaerapy to bring our soft mist inhaler technology to patients suffering from PAH,” said Bernhard Müllinger, general manager and COO of Resyca.

“This agreement demonstrates our commitment to delivering innovative solutions to the pharmaceutical industry, and we are confident that our technology will significantly improve the lives of patients affected by this debilitating and progressive condition.”

Thaerapy BV is a drug product development company focused on the development of inhaled combination products for the treatment of pulmonary hypertension.

Wilbur de Kruijf, CEO of Thaerapy BV, said: “We are excited to be partnering with Resyca, a company with a proven track record of delivering high-quality and innovative inhaler technology.

“With Resyca’s support and expertise, we are well-positioned to advance our mission of bringing innovative and life-changing treatments to PAH patients.”

Weak heart muscle

With PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs, and blood pressure in the lung arteries rises. The heart then must work harder to pump blood through the lungs. The extra effort eventually causes the heart muscle to become weak and fail.

In some people, pulmonary hypertension slowly gets worse and can be life-threatening. Although there's no cure for some types of pulmonary hypertension, treatment can help reduce symptoms and improve quality of life.

The signs of PAH develop slowly and patients may be unaware they have them for months or even years. They will get worse as the disease progresses.

Symptoms include chest pressure or pain, blue lips and skin, dizziness, fast pulse or pounding heartbeat, fatigue, shortness of breath at the start of exercise and eventually while resting. Swelling in the ankles, legs and eventually the abdomen.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us


View more